J. Molner (MOLNR) H2 2025 earnings summary

Executive summary

• Strengthened position in the U.S. generic pharmaceuticals market with new product launches and strategic collaborations for portfolio expansion and long-term growth.

• Launched two new dermatology prescription products in the U.S., bringing the total to four commercial products.

• Entered new development agreements with U.S. partners, retaining asset ownership and recognizing some inflows as advance payments.

• Added two new wholesale customers, expanding U.S. market access.

• Undertook capital restructuring, increasing share capital and converting part of loan liabilities into equity.

Financial highlights

• Reported revenue declined 50% year-over-year to €1,146,274; adjusted revenue was €2,461,986.

• EBITDA improved to €552,151 from a loss of €1,827,186 in 2024; adjusted EBITDA was €1,867,863.

• Net profit was €127,891, a turnaround from a €2,438,621 loss in 2024; adjusted net profit was €1,443,603.

• Direct costs were €1,009,140 (88% of revenue); operating expenses rose 1% to €1,224,310.

• Cash balance at year-end was €214,483, nearly unchanged from 2024.

Outlook and guidance

• Focus remains on U.S. market expansion, portfolio growth, and strengthening financial structure for sustainable growth.

• Management highlights the need for additional funding to support ongoing operations and growth.